Loading...
•
Dec 31, 2022
Eli Lilly Q4 2022 Earnings Report
Eli Lilly reported a decrease in revenue but an increase in EPS on a reported basis for Q4 2022. The company highlighted pipeline advancements and key growth products driving revenue.
Key Takeaways
Eli Lilly's Q4 2022 results showed a 9% decrease in revenue, but excluding COVID-19 antibodies, revenue increased by 5%. EPS increased by 13% on a reported basis. The company is focusing on launching new medicines and advancing its pipeline.
Q4 2022 revenue decreased by 9%, but excluding COVID-19 antibodies, revenue increased by 5%.
Key growth products grew by 21% and represented 70% of revenue in Q4 2022.
Q4 2022 EPS increased 13% to $2.14 on a reported basis.
2023 EPS guidance updated to be in the range of $7.90 to $8.10 on a reported basis and $8.35 to $8.55 on a non-GAAP basis.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Mounjaro Revenue
CapyFin.comVerzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
Lilly updated its 2023 financial guidance, increasing EPS guidance due to changes in the tax rate.
Positive Outlook
- Revenue guidance unchanged at $30.3 to $30.8 billion
- Gross Margin % of Revenue (reported) remains approximately 77%
- Gross Margin % of Revenue (non-GAAP) remains approximately 79%
- Marketing, Selling & Administrative expenses unchanged at $6.9 to $7.1 billion
- Research & Development expenses unchanged at $8.2 to $8.4 billion
Challenges Ahead
- Other Income/(Expense) unchanged at $(200) to $(100) million
- Tax Rate updated to approximately 13% (previously approximately 16%)
- Earnings per Share (reported) updated to $7.90 to $8.10 (previously $7.65 to $7.85)
- Earnings per Share (non-GAAP) updated to $8.35 to $8.55 (previously $8.10 to $8.30)
- 2023 financial guidance does not include any acquired IPR&D and development milestone charges
Revenue & Expenses
Visualization of income flow from segment revenue to net income